Method for treating schizophrenia and related diseases
View Patent ↗The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
1. A method for treating schizophrenia and/or bipolar disorder which comprises administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof, and a therapeutically effective amount of a mGluR2 ligand to a mammal in need thereof.
2. The method of claim 1 wherein treating schizophrenia and/or bipolar disorder is treating schizophrenia.
3. The method of claim 2 wherein treating schizophrenia is improving (i) positive symptoms in schizophrenia, (ii) negative symptoms in schizophrenia, and/or (iii) cognitive impairment associated with schizophrenia.
4. The method of claim 2 wherein treating schizophrenia is improving cognitive impairment associated with schizophrenia.
5. A method for improving cognitive impairment associated with schizophrenia which comprises administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof, and a therapeutically effective amount of a mGluR2 ligand to a mammal in need thereof.
6. The method of claim 1 wherein the mGluR2 ligand is a mGluR2 agonist.
7. The method of claim 1 wherein the mGluR2 ligand is a mGluR2 positive allosteric modulator.
8. The method of claim 1 wherein the mGluR2 ligand is one or more selected from the group consisting of LY404039, LY2140023, LY379268, LY354740 (eglumetad), LY354740 monohydrate, TS-032, AZD-8529, ADX71149, MGS-0008, MGS-0028, MGS-0039, MGS-0210, BINA, LY487379, and pharmaceutically acceptable salts thereof.
9. The method of claim 1 wherein the mGluR2 ligand is one or more selected from the group consisting of LY379268, LY2140023, LY404039, LY354740 (eglumetad), and pharmaceutically acceptable salts thereof.
10. The method of claim 1 wherein the mGluR2 ligand is one or more selected from the group consisting of LY379268, LY404039, BINA, and pharmaceutically acceptable salts thereof.
11. The method of claim 1 wherein the mGluR2 ligand is one or more selected from the group consisting of LY404039 and pharmaceutically acceptable salts thereof.